The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines

Cell Proliferation

Volumn 45, Issue 6, 2012, Pages 545-556

  Carmazzi, Y ^a   Iorio, M ^b   Armani, C ^a   Cianchetti, S ^a   Raggi, F ^b   Neri, T ^a   Cordazzo, C ^a,c   Petrini, S ^a   Vanacore, R ^b   Bogazzi, F ^b   Paggiaro, P ^a   Celi, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c National Institute for Cardiovascular Research INRC   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DALTEPARIN; FONDAPARINUX; MESSENGER RNA; NADROPARIN; PROTEIN P21; PROTEIN TYROSINE PHOSPHATASE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTICOAGULANTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; LUNG; LUNG NEOPLASMS; NADROPARIN;

EID: 84868124456     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2012.00847.x     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
2. Molina JR, Adjei AA, Jett JR (2006) Advances in chemotherapy of non-small cell lung cancer. Chest 130, 1211-1219.
3. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N. Engl. J. Med. 359, 1367-1380.
4. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22, 1944-1948.
5. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A et al. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2, 1266-1271.
6. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23, 2130-2135.
7. Conti I, Rollins BJ (2004) CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 14, 149-154.
8. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA 98, 3352-3357.
9. Norrby K, Ostergaard P (1997) A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int. J. Microcirc. Clin. Exp. 17, 314-321.
10. Fasciano S, Patel RC, Handy I, Patel CV (2005) Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1). J. Biol. Chem. 280, 15682-15689.
11. Patel RC, Handy I, Patel CV (2002) Contribution of double-stranded RNA-activated protein kinase toward antiproliferative actions of heparin on vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22, 1439-1444.
12. Mousa SA, Petersen LJ (2009) Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb. Haemost. 102, 258-267.
13. Chen X, Xiao W, Qu X, Zhou S (2008) The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. Cancer Invest. 26, 718-724.
14. Fareed J, Hoppensteadt D, Schultz C, Ma Q, Kujawski MF, Neville B et al. (2004) Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr. Pharm. Des. 10, 983-999.
15. Nicolau JC, Cohen M, Montalescot G (2009) Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes. J. Cardiovasc. Pharmacol. 53, 440-445.
16. Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25(Suppl. 3), 5-16.
17. Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R et al. (2004) Generic low-molecular-weight heparins: some practical considerations. Semin. Thromb. Hemost. 30, 703-713.
18. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
19. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353-2362.
20. Duverger V, Sartorius U, Klein-Bauernschmitt P, Krammer PH, Schlehofer JR (2002) Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int. J. Cancer 97, 706-712.
21. Ohi R, Gould KL (1999) Regulating the onset of mitosis. Curr. Opin. Cell Biol. 11, 267-273.
22. Lew DJ, Kornbluth S (1996) Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr. Opin. Cell Biol. 8, 795-804.
23. Donzelli M, Draetta GF (2003) Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677.
24. Edelman MJ (2006) Novel cytotoxic agents for non-small cell lung cancer. J. Thorac. Oncol. 1, 752-755.
25. Norrby K (2006) Low-molecular-weight heparins and angiogenesis. APMIS 114, 79-102.
26. Debergh I, Van Damme N, Pattyn P, Peeters M, Ceelen WP (2010) The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br. J. Cancer 102, 837-843.
27. Castellot JJJ, Addonizio ML, Rosenberg R, Karnovsky MJ (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J. Cell Biol. 90, 372-379.
28. Clowes AW, Clowes MM (1987) Regulation of smooth muscle proliferation by heparin in vitro and in vivo. Int. Angiol. 6, 45-51.
29. King RW, Jackson PK, Kirschner MW (1994) Mitosis in transition. Cell 79, 563-571.
30. Morgan DO (1995) Principles of CDK regulation. Nature 374, 131-134.
31. Satyanarayana A, Kaldis P (2009) Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28, 2925-2939.
32. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246, 629-634.
33. Porter LA, Donoghue DJ (2003) Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res. 5, 335-347.
34. Gavet O, Pines J (2010) Progressive activation of cyclin B1-Cdk1 coordinates entry to mitosis. Dev. Cell 18, 533-543.
35. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG (1998) Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82, 396-403.
36. Sprague S, Cook DJ, Anderson D, O'Brien BJ (2003) A systematic review of economic analyses of low-molecular-weight heparin for the treatment of venous thromboembolism. Thromb. Res. 112, 193-201.
37. Camporese G, Bernardi E (2009) Low-molecular-weight heparin for thromboprophylaxis. Curr. Opin. Pulm. Med. 15, 443-454.
38. Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brucke P et al. (1997) Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J. Surg. 21, 2-8; discussion 8-9.
39. Sudhalter J, Folkman J, Svahn CM, Bergendal K, D'Amore PA (1989) Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin. J. Biol. Chem. 264, 6892-6897.
40. Bianchini P, Liverani L, Spelta F, Mascellani G, Parma B (2007) Variability of heparins and heterogeneity of low molecular weight heparins. Semin. Thromb. Hemost. 33, 496-502.
41. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J et al. (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. 73, 630-640.
42. Turpie AG, Eriksson BI, Lassen MR, Bauer KA (2003) Fondaparinux, the first selective factor Xa inhibitor. Curr. Opin. Hematol. 10, 327-332.
43. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J (1997) Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb. Res. 86, 1-36.
44. Papathanasopoulos A, Kouroupis D, Henshaw K, McGonagle D, Jones EA, Giannoudis PV (2011) Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells. J. Orthop. Res. 29, 1327-1335.
45. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br. J. Surg. 92, 177-183.
46. Khorana AA, Sahni A, Altland OD, Francis CW (2003) Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler. Thromb. Vasc. Biol. 23, 2110-2115.